BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 24004591)

  • 41. Trilinolein inhibits proliferation of human non-small cell lung carcinoma A549 through the modulation of PI3K/Akt pathway.
    Chou PY; Huang GJ; Pan CH; Chien YC; Chen YY; Wu CH; Sheu MJ; Cheng HC
    Am J Chin Med; 2011; 39(4):803-15. PubMed ID: 21721158
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Daidzein induced apoptosis via down-regulation of Bcl-2/Bax and triggering of the mitochondrial pathway in BGC-823 cells.
    Tang S; Hu J; Meng Q; Dong X; Wang K; Qi Y; Chu C; Zhang X; Hou L
    Cell Biochem Biophys; 2013 Mar; 65(2):197-202. PubMed ID: 22926545
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Leptin stimulates ovarian cancer cell growth and inhibits apoptosis by increasing cyclin D1 and Mcl-1 expression via the activation of the MEK/ERK1/2 and PI3K/Akt signaling pathways.
    Chen C; Chang YC; Lan MS; Breslin M
    Int J Oncol; 2013 Mar; 42(3):1113-9. PubMed ID: 23354006
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
    Janmaat ML; Kruyt FA; Rodriguez JA; Giaccone G
    Clin Cancer Res; 2003 Jun; 9(6):2316-26. PubMed ID: 12796401
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Effects of zhiling capsule on the proliferation inhibition and apoptosis induction in human small cell lung cancer cell line NCI-H446].
    Chen YY; Pan YL; Liu TB
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2007 Jun; 27(6):531-4. PubMed ID: 17633367
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mechanisms involved in resveratrol-induced apoptosis and cell cycle arrest in prostate cancer-derived cell lines.
    Benitez DA; Pozo-Guisado E; Alvarez-Barrientos A; Fernandez-Salguero PM; Castellón EA
    J Androl; 2007; 28(2):282-93. PubMed ID: 17050787
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Expression and significance of MAPK/ERK in the specimens and cells of epithelial ovarian cancer].
    Jiang XL; Gao JC; Jiang L; Zhang PX; Kang TJ; Sun Q; Qi WJ; Zhang QP; Guan HW; Shi H
    Zhonghua Fu Chan Ke Za Zhi; 2019 Aug; 54(8):541-547. PubMed ID: 31461811
    [No Abstract]   [Full Text] [Related]  

  • 48. Delphinidin reduces cell proliferation and induces apoptosis of non-small-cell lung cancer cells by targeting EGFR/VEGFR2 signaling pathways.
    Pal HC; Sharma S; Strickland LR; Agarwal J; Athar M; Elmets CA; Afaq F
    PLoS One; 2013; 8(10):e77270. PubMed ID: 24124611
    [TBL] [Abstract][Full Text] [Related]  

  • 49. AZD6244 inhibits cisplatin-induced ERK1/2 activation and potentiates cisplatin-associated cytotoxicity in K-ras G12D preclinical models.
    Kim EY; Kim A; Kim SK; Chang YS
    Cancer Lett; 2015 Mar; 358(1):85-91. PubMed ID: 25541062
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Norcantharidin inhibits growth of human gallbladder carcinoma xenografted tumors in nude mice by inducing apoptosis and blocking the cell cycle in vivo.
    Fan YZ; Zhao ZM; Fu JY; Chen CQ; Sun W
    Hepatobiliary Pancreat Dis Int; 2010 Aug; 9(4):414-22. PubMed ID: 20688607
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/β-catenin pathways.
    Galuppo R; Maynard E; Shah M; Daily MF; Chen C; Spear BT; Gedaly R
    Anticancer Res; 2014 Apr; 34(4):1709-13. PubMed ID: 24692700
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bcl-2/Bcl-xL inhibition increases the efficacy of MEK inhibition alone and in combination with PI3 kinase inhibition in lung and pancreatic tumor models.
    Tan N; Wong M; Nannini MA; Hong R; Lee LB; Price S; Williams K; Savy PP; Yue P; Sampath D; Settleman J; Fairbrother WJ; Belmont LD
    Mol Cancer Ther; 2013 Jun; 12(6):853-64. PubMed ID: 23475955
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer.
    Tentler JJ; Nallapareddy S; Tan AC; Spreafico A; Pitts TM; Morelli MP; Selby HM; Kachaeva MI; Flanigan SA; Kulikowski GN; Leong S; Arcaroli JJ; Messersmith WA; Eckhardt SG
    Mol Cancer Ther; 2010 Dec; 9(12):3351-62. PubMed ID: 20923857
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Signaling networks associated with AKT activation in non-small cell lung cancer (NSCLC): new insights on the role of phosphatydil-inositol-3 kinase.
    Scrima M; De Marco C; Fabiani F; Franco R; Pirozzi G; Rocco G; Ravo M; Weisz A; Zoppoli P; Ceccarelli M; Botti G; Malanga D; Viglietto G
    PLoS One; 2012; 7(2):e30427. PubMed ID: 22363436
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer.
    Ku BM; Bae YH; Lee KY; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Invest New Drugs; 2020 Apr; 38(2):360-368. PubMed ID: 31124056
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer.
    Molina-Arcas M; Hancock DC; Sheridan C; Kumar MS; Downward J
    Cancer Discov; 2013 May; 3(5):548-63. PubMed ID: 23454899
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mutant HRAS as novel target for MEK and mTOR inhibitors.
    Kiessling MK; Curioni-Fontecedro A; Samaras P; Atrott K; Cosin-Roger J; Lang S; Scharl M; Rogler G
    Oncotarget; 2015 Dec; 6(39):42183-96. PubMed ID: 26544513
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Synergistic Antitumor Effect of Taxanes and CDK4/6 Inhibitor in Lung Cancer Cells and Mice Harboring KRAS Mutations.
    Son KH; Kim MY; Shin JY; Kim JO; Kang JH
    Anticancer Res; 2021 Oct; 41(10):4807-4820. PubMed ID: 34593430
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines.
    Garon EB; Finn RS; Hosmer W; Dering J; Ginther C; Adhami S; Kamranpour N; Pitts S; Desai A; Elashoff D; French T; Smith P; Slamon DJ
    Mol Cancer Ther; 2010 Jul; 9(7):1985-94. PubMed ID: 20587667
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Synergy of theophylline reduces necrotic effect of berberine, induces cell cycle arrest and PARP, HMGB1, Bcl-2 family mediated apoptosis in MDA-MB-231 breast cancer cells.
    Hashemi-Niasari F; Rabbani-Chadegani A; Razmi M; Fallah S
    Biomed Pharmacother; 2018 Oct; 106():858-867. PubMed ID: 30119256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.